ClickPET offers technical solutions for simplifying the production of disease specific biomolecule-based radiopharmaceuticals for positron emission tomography (PET) for aiding patient selection, cancer staging and disease follow-up by diagnostic imaging. The company’s technology enables the speeding-up of new radiotracer development facilitating the discovery of new diagnostic methods for personalized medicine.

 

  • Founding year:
  • R2B project started in January 2022
  • Development phase:
  • Prototype
  • Funding stage:
  • Pre-seed in 2024
  • Website:
  • Contact person info:
  • raymond.li(at)helsinki.fi
  • Team members:
  • 7